Filing Flows › BridgeBio Pharma (BBIO) › Stock forecast & fair value
BridgeBio Pharma (BBIO) stock forecast and fair value
BridgeBio Pharma (BBIO) trades at $74.29. 20 analysts' median price target is $107.50 (+45%), from $80.00 to $156.00. Across 16 valuation methods the middle fair value is $16.64 (-78%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $5.39 | $13.23 | $30.82 | -82% |
| EV/Sales vs peers, weighted | $10.08 | $20.73 | $35.93 | -72% |
| Sum of the parts (segments × peer EV/Sales) | $12.90 | $24.36 | $48.57 | -67% |
| Sum of the parts, weighted (segments × weighted peer EV/Sales) | $21.62 | $40.20 | $62.44 | -46% |
| Analysts' price targets | $80.00 | $106.85 | $156.00 | +44% |
| Shareholder yield (dividends + buybacks) | $3.08 | $3.51 | $4.08 | -95% |
| Path-to-margin DCF | $4.76 | $14.09 | $23.42 | -81% |
| Path-to-margin DCF, dilution-adjusted | $4.76 | $14.09 | $23.42 | -81% |
| Exit-multiple (venture) method | $17.30 | $32.04 | $73.55 | -57% |
| EV/Sales vs Rule of 40 (all-company fit) | $0.13 | $10.14 | $37.61 | -86% |
BridgeBio Pharma's latest quarter
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BBIO stock?
The median of 20 analysts' 12-month targets is $107.50, +45% from $74.29; the range is $80.00 to $156.00. The average rating is strong buy.
What is BridgeBio Pharma's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $3.51 and $106.85, with a middle value of $16.64 against a price of $74.29. Each method's assumptions are on the page.
Does BridgeBio Pharma usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is BBIO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.